FRAX® in Hemodialysis with Osteoporosis- A Registry Study

Weicheng Huang,Yuwei Wang,Chao‐Tung Chen,Ying‐Chou Chen
DOI: https://doi.org/10.29011/2688-7460.100210
2023-01-01
Family Medicine and Primary Care Open Access
Abstract:Objectives:The best way to find out which hemodialysis patients are at high fracture risk is uncertain.The primary purpose of this study was to analyze the use of the Fracture Risk Assessment Tool (FRAX ® ) in hemodialysis subjects.Methods: Participants were recruited by the nephrology and family department.Each participant was to complete the structured questionnaire, which included the clinical risk factors specifically for the FRAX ® calculation tool.Results: A total of 450 patients were enrolled.The age of the patients was 64 years (IQR, 58-70).Most of the patients were female (74.7%).The duration of hemodialysis was 3 years (IQR, 2-5).There was high correlation found between the 10-yr major osteoporotic fracture probabilities calculated with and without Bone Mineral Density (BMD) (p < 0.001).There was also correlation in terms of hip fractures risk.When we divided the patients into normal femoral neck BMD, osteopenia, and osteoporosis, there is still high correlation between those with and without BMD.12.7% with BMD and 7.3% without BMD were above treatment threshold by major osteoporotic fracture risk, while 48.0% with BMD and 33.3% without BMD were above treatment threshold by hip fracture risk.Conclusions: FRAX is valuable in assess fracture risk in hemodialysis patients.FRAX ® with and without BMD had high correlation with each other in hemodialysis patients.FRAX-based intervention thresholds are helpful for health economic assessment and to avoid unnecessary treatment.
What problem does this paper attempt to address?